In melanoma, anti-PD-1 treatment also increases the inhibitory immune checkpoint, VISTA, that synergistically inhibits T cell activation with PD-L1, leading to adaptive resistance; its expression is higher than that of PD-L1 in CRC [93]. The gene discussed is CD274; the disease is colorectal carcinoma.